ALIM - ALIMERA SCIENCES INC
IEX Last Trade
5.54
5.540 100.000%
Share volume: 0
Last Updated: Mon 16 Sep 2024 11:23:18 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
Fundamental analysis
20%
Profitability
14%
Dept financing
25%
Liquidity
75%
Performance
10%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
0 0%
6 Months
0.36%
1 Year
43.52%
2 Year
140.87%
Key data
Stock price
$5.54
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.92 - $5.63
52 WEEK CHANGE
$43.90
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/24/2024
Company detail
CEO: Richard S. Eiswirth
Region: US
Website: alimerasciences.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: alimerasciences.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Alimera Sciences, Inc. offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME) The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Recent news